SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharma launches Fexuprazan tablets 40 mg in India

07 Apr 2025 Evaluate

Sun Pharmaceutical Industries has launched Fexuprazan tablets 40 mg in India under the brand name ‘FEXUCLUE’. FEXUCLUE, a novel potassium competitive acid blocker (PCAB), is approved as a new treatment for adults with Erosive Esophagitis of all grades. 

The company has obtained rights from Daewoong Pharmaceutical Co, Korea to manufacture and commercialise FEXUCLUE (Fexuprazan) in India. As per agreement terms, Daewoong will be entitled to upfront and milestone payments, including royalties. 

Sun Pharmaceutical Industries is among the largest specialty generic pharmaceutical company and India's top pharmaceutical company.


Sun Pharma Inds. Share Price

1851.90 4.60 (0.25%)
11-May-2026 09:54 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1851.90
Dr. Reddys Lab 1273.00
Cipla 1332.95
Zydus Lifesciences 933.90
Lupin 2245.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×